Annals of Oncology 12:S15-S19, 2001
© 2001 European Society for Medical Oncology
Symposium Article |
HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
The Molecular Targeting Unit, Istituto Nazionale Tumori Milan, Italy
Correspondence to. S. Ménard, MD Molecular Targeting Unit Department of Experimental Oncology Istituto Nazionale Tumori Via Venezian 1 20133 Milan Italy E-mail: menard{at}istitutotumori.mi.it
To date, poor standardization in HER2 status evaluation has precluded reliable comparison of overexpression rates in different tumors. However, standardized methodologies have been introduced recently for these analyses, and have identified frequencies of 51%, 44%, 26% and 25% in Wilm's tumor, bladder, pancreatic and breast carcinoma, respectively. Other tumors tested had frequencies below 20%. The frequency was greater than that predicted by gene amplification data in some tumor types, which may indicate overexpression due to gene deregulation, rather than gene amplification. Analysis of a large retrospective series of breast carcinomas demonstrated an association between HER2 positivity and a number of other prognostic markers. Together, these variables identify a subset of tumors with poor prognosis and early relapse post-surgery. HER2 expression is relatively stable, with 95% concordance between the HER2 status of primary and metastatic lesions. However, contralateral tumors are unrestricted with regard to HER2 status. Preliminary data indicate that the HER2 status of a hormone receptor-positive tumor may fluctuate according to the menstrual cycle. It is anticipated that the emerging wealth of standardized data for HER2 status will help to elucidate the role of HER2 in tumor progression.
breast cancer, gene regulation, HER2, Herceptin, immunohistochemical, trastuzumab
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Wu, L. Jung, A. B. Cooper, C. Fleet, L. Chen, L. Breault, K. Clark, Z. Cai, S. Vincent, S. Bottega, et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice PNAS, April 28, 2009; 106(17): 7022 - 7027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard, and E. Tagliabue Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab Clin. Cancer Res., March 15, 2009; 15(6): 2010 - 2021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, et al. Prognostic factors in 1038 women with metastatic breast cancer Ann. Onc., July 17, 2008; (2008) mdn424v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Spangenberg, E. U. Lausch, T. M. Trost, D. Prawitt, A. May, R. Keppler, S. A. Fees, D. Reutzel, C. Bell, S. Schmitt, et al. ERBB2-Mediated Transcriptional Up-regulation of the {alpha}5{beta}1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions. Cancer Res., April 1, 2006; 66(7): 3715 - 3725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Begon, L. Delacroix, D. Vernimmen, P. Jackers, and R. Winkler Yin Yang 1 Cooperates with Activator Protein 2 to Stimulate ERBB2 Gene Expression in Mammary Cancer Cells J. Biol. Chem., July 1, 2005; 280(26): 24428 - 24434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanner, M. Hollmen, T. T. Junttila, A. I. Kapanen, S. Tommola, Y. Soini, H. Helin, J. Salo, H. Joensuu, E. Sihvo, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II{alpha} gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann. Onc., February 1, 2005; 16(2): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-M. Xu, L.-F. Wang, L.-T. Jia, X.-C. Qiu, J. Zhao, C.-J. Yu, R. Zhang, F. Zhu, C.-J. Wang, B.-Q. Jin, et al. A Caspase-6 and Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Antibody Chimeric Molecule Suppresses the Growth of HER2-Overexpressing Tumors J. Immunol., July 1, 2004; 173(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger Coregulation of Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 (HER2) Levels and Locations: Quantitative Analysis of HER2 Overexpression Effects Cancer Res., March 1, 2003; 63(5): 1130 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tikhomirov and G. Carpenter Identification of ErbB-2 Kinase Domain Motifs Required for Geldanamycin-induced Degradation Cancer Res., January 1, 2003; 63(1): 39 - 43. [Abstract] [Full Text] [PDF]
|
|